Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
SCC, BCC Immunotherapy
San Francisco - Topical immunomodulators, specifically imiquimod 5 percent cream (Aldara), may be a viable option for treating patients with invasive squamous cell carcinoma (SCC) or aggressive basal cell carcinoma (BCC) who are no longer candidates for surgery, said Ulrich Hengge, M.D.
Related Videos
Related Content
